News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epigenomics AG and QIAGEN Inc. (QGEN) Sign Collaboration Agreement in Colorectal Cancer Blood Testing



2/28/2011 9:08:33 AM

BERLIN & SEATTLE--(BUSINESS WIRE)--Epigenomics AG (FWB:ECX), the cancer molecular diagnostics company, and QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that the companies have entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test based on Epigenomics’ proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES